Rekvina Laboratories Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials & compliance.
CIN L24231GJ1988PLC011458 Incorporated 01 November 1988 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - BSE: 526075 Public Limited Company pharma
Market Cap
₹87.37 Cr
VINRKLB · BSE
Share Price
₹80.17
+2.00% today
Revenue
₹1.27 Cr
FY 2025-26
EBITDA
−₹0.25 Cr
Margin -19.7%
Net Profit
−₹0.25 Cr
FY 2025-26 · -92.3% YoY
Authorised capital
₹3.5 Cr
Registered with MCA
Paid-up capital
₹3.01 Cr
Issued & subscribed
Open charges
₹8.04 Cr
Secured borrowings

About Rekvina Laboratories Limited

Data last updated:

Rekvina Laboratories Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 November 1988 and has been in existence for over 38 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1988PLC011458. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 526075.

The company has an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.01 Cr. It was formerly known as Rekvina Laboratories Private Limited. It is led by directors including Amit Mukesh Shah (Managing Director) and Ila Rajendra Pathak.

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Vadodara, Gujarat.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹1.27 Cr. For the same year it recorded a net loss of ₹25 Lakh (net margin -19.7%) and EBITDA of -₹25 Lakh (EBITDA margin -19.7%). Total assets are valued at ₹24 Lakh (up 366.7% YoY).

The company is associated with 1 brand: Rekvina Laboratories. As per MCA filings, the company has open charges of ₹8.04 Cr on record. Court records list 8 cases involving the company, including 5 filed by the company and 3 filed against it. The company has 81 deals on record (81 market trades); the latest was in June 2018.

The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website rekvinalaboratories.com.

Company details

CIN L24231GJ1988PLC011458
Registration Number 011458
Incorporation Date 01 November 1988
ROC Ahmedabad
Listing Status Listed - Listed on BSE (526075)
Company Status Active
Compliance Status Active Non-Compliant

CIN history

Rekvina Laboratories has one previous CIN (Corporate Identification Number): U24231GJ1988PLC011458. The current CIN is L24231GJ1988PLC011458, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231GJ1988PLC011458Current
U24231GJ1988PLC011458Previous

Contact details

Rekvina Laboratories Limited's registered office is in Vadodara, Gujarat. Its website is rekvinalaboratories.com. Its e-mail address is in the company report.

  • Email
  • Registered Address
    36 Sampatrao Colony, Next To Royal Hotel, Vadodara, Gujarat, India – 390007
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Rekvina Laboratories Limited, buy the company report.

Comprehensive company report
Rekvina Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Rekvina Laboratories operates one associated brand: Rekvina Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Medicines for gynecological disorders and surgical therapeutics are developed.rekvinalaboratories.com

Financials of Rekvina Laboratories Limited

FY 2025-26 filings available

Rekvina Laboratories Limited reported revenue of ₹1.27 Cr for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹1.27 Cr
EBITDA
−₹0.25 Cr
-92.3% YoY
Profit After Tax
−₹0.25 Cr
-92.3% YoY
Net Worth
−₹1.23 Cr
-261.8% YoY
Total Assets
₹0.24 Cr
+366.7% YoY
Total Debt
₹1.47 Cr
+488.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1.270.000.000.000.000.000.00
EBITDA(0.25)(0.13)(0.02)0.00(0.08)(0.07)(0.15)
EBITDA margin-19.7%------
Profit before tax(0.25)(0.13)(0.02)0.00(0.08)(0.07)0.00
Net profit(0.25)(0.13)(0.02)0.00(0.08)(0.07)0.00
Net profit margin-19.7%------
EPS (₹)(0.42)(0.23)(0.03)0.00(0.13)(0.11)0.00
Balance sheet
Total assets0.24(0.09)(0.16)0.090.010.090.16
Net worth(1.23)(0.34)(0.20)0.010.010.090.15
Total debt1.470.250.040.080.000.000.00
Cash & bank0.020.030.010.010.000.000.01
Net working capital0.26(0.08)(0.16)(0.10)(0.18)(0.14)(0.08)
Cash flow
Cash from operations(0.59)(0.19)(0.01)0.01(0.04)(0.01)-
Cash from investing0.000.000.000.000.040.00-
Cash from financing0.580.210.010.000.000.00-
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.590.670.720.350.200.000.000.00
Revenue growth (YoY)+195.0%-------
Other income0.000.000.000.000.000.000.000.00
Total expenses0.650.790.780.470.230.040.040.02
EBITDA(0.06)(0.12)(0.06)(0.12)(0.03)(0.04)(0.04)(0.02)
EBITDA margin-10.2%-17.9%-8.3%-34.3%-15.0%---
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax(0.06)(0.12)(0.06)(0.12)(0.03)(0.04)(0.04)(0.02)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.590.670.720.350.200.000.000.00
Revenue growth (YoY)+195.0%-------
Other income0.000.000.000.000.000.000.000.00
Total expenses0.650.790.780.470.230.040.040.02
EBITDA(0.06)(0.12)(0.06)(0.12)(0.03)(0.04)(0.04)(0.02)
EBITDA margin-10.2%-17.9%-8.3%-34.3%-15.0%---
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax(0.06)(0.12)(0.06)(0.12)(0.03)(0.04)(0.04)(0.02)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1.270.000.000.000.000.000.00
Other income0.000.000.000.000.000.000.15
Total expenses1.520.130.020.000.080.070.15
Employee cost0.230.040.000.000.000.000.08
EBITDA(0.25)(0.13)(0.02)0.00(0.08)(0.07)(0.15)
EBITDA margin-19.7%------
Depreciation0.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.00
Profit before tax(0.25)(0.13)(0.02)0.00(0.08)(0.07)0.00
Tax0.000.000.000.000.000.000.00
Net profit(0.25)(0.13)(0.02)0.00(0.08)(0.07)0.00
Net profit margin-19.7%------
EPS (₹)(0.42)(0.23)(0.03)0.00(0.13)(0.11)0.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.013.013.013.013.013.013.01
Reserves & surplus(4.24)(3.35)(3.21)(3.00)(3.00)(2.92)(2.86)
Shareholders' funds (net worth)(1.23)(0.34)(0.20)0.010.010.090.15
Secured loans0.000.000.000.000.000.000.00
Unsecured loans1.470.250.040.080.000.000.00
Total debt1.470.250.040.080.000.000.00
Total liabilities0.24(0.09)(0.16)0.090.010.090.16
Assets
Gross block0.000.000.000.510.510.510.39
Net block0.000.000.000.140.140.140.14
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.050.050.050.05
Inventories0.000.000.000.000.000.000.00
Sundry debtors0.600.000.000.000.000.000.00
Cash & bank balances0.020.030.010.010.000.000.01
Loans & advances0.580.010.000.000.000.010.03
Total current assets1.200.040.010.010.000.010.04
Total current liabilities0.940.120.170.110.180.150.12
Net working capital0.26(0.08)(0.16)(0.10)(0.18)(0.14)(0.08)
Total assets0.24(0.09)(0.16)0.090.010.090.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.030.010.010.000.000.01-
Net cash from operating activities(0.59)(0.19)(0.01)0.01(0.04)(0.01)-
Net cash from investing activities0.000.000.000.000.040.00-
Net cash from financing activities0.580.210.010.000.000.00-
Net change in cash(0.01)0.020.000.010.00(0.01)-
Closing cash0.020.030.010.010.000.00-
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
EBITDA growth-92.3%-550.0%-+100.0%-14.3%+53.3%-
PBT growth-92.3%-550.0%+9997.0%+9997.0%-14.3%+9997.0%+9997.0%
Net income growth-92.3%-550.0%-+100.0%-14.3%--
Revenue CAGR (3Y)-------100.0%
EBITDA CAGR (3Y)-+17.6%-34.1%-100.0%-7.2%+20.5%+35.7%
Profitability & leverage
Net income margin-19.7%------
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%-
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%-
Debt / equity0.000.000.004.000.000.00-
Long-term debt / equity0.000.000.00-0.070.000.00-
Interest cover0.000.000.00-0.000.000.00
Efficiency & per share
Fixed asset turnover0.000.000.000.000.000.00-
Inventory turnover0.000.000.000.000.000.00-
Debtors turnover4.230.000.000.000.000.00-
EPS (₹)(0.42)(0.23)(0.03)0.00(0.13)(0.11)0.00
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)(2.04)(0.55)(0.32)0.020.020.150.26

To see the full year-wise statements and ratios of Rekvina Laboratories Limited, buy the company report.

Board of directors of Rekvina Laboratories Limited

Rekvina Laboratories has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Amit Mukesh ShahManaging Director01 Aug 200026 Years 3 MonthsCurrent
Jay Chintan PatelAdditional Director29 Jan 20260 Years 9 MonthsCurrent
Ila Rajendra PathakDirector02 Sep 20242 Years 2 MonthsCurrent
Prateek JainAdditional Director06 Oct 20251 Years 1 MonthsCurrent
Surbhit Mukesh ShahDirector27 Sep 20242 Years 1 MonthsCurrent

Auditor

Rekvina Laboratories Limited is audited by JIGAR ADHYARU & CO for the financial year 2023.

Auditor firmFinancial yearFirm registration number
JIGAR ADHYARU & COFY 2023142223W

Shareholding

Shareholding for the quarter ended Jun 2026: promoters hold 41.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 58.70%.

Promoters: 41.30%Retail & Others: 58.70%
Jun 2026
QUARTER
41.30% Promoters
58.70% Retail & Others
Promoter holding - history
Now 41.30% · Jun 2026High 41.30% · Sep 2025Low 41.30% · Sep 2025
40%40.8%41.5%42.3%43%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 41.30%Dec 2025: 41.30%Mar 2026: 41.30%Jun 2026: 41.30%41.30%41.30%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters41.30%41.30%41.30%41.30%
Public58.70%58.70%58.70%58.70%

Charges & borrowings

Open charges
₹8.04 Cr
Satisfied charges
None
Breakdown by lending institutions
Bank of Baroda₹6.95 Cr
Industrial Devlopment Bank of India₹0.80 Cr
Gujrat State Financial Corportion₹0.29 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Dec 220390100140Bank of Baroda₹5 LakhOpen
13 Jul 199990099030Bank of Baroda₹1.9 CrOpen
24 Sep 199790096485Bank of Baroda₹1.9 CrOpen
13 Jul 199490097921Bank of Baroda₹1.9 CrOpen
10 Dec 199390097799Bank of Baroda₹53 LakhOpen

To see the full charge records of Rekvina Laboratories Limited, buy the company report.

Total charge records: 10 View all charges

Deals & funding

Rekvina Laboratories Limited has 81 deals on record (81 market trades); the latest was in June 2018.

Total deals
81
Market trades
81

Deals on record (5 of 81)

WhenDealAmountParties
Jun 2018Market trade₹7.3 LakhBuyer: 2 individuals
Seller: Arcadia Share and Stock Brokers Private Limited
Jun 2018Market trade₹7.9 LakhBuyer: 2 individuals
Seller: Arcadia Share and Stock Brokers Private Limited
Apr 2017Market trade₹9.6 LakhBuyer: 3 individuals
Seller: GN Credits Private Limited , 2 individuals
Oct 2016Market trade₹19.1 LakhBuyer: Ashamakam Mercantile Private Limited , 3 individuals
Seller: 3 individuals
Sep 2016Market trade₹2.8 LakhBuyer: Ashamakam Mercantile Private Limited
Seller: an individual

To see the full deal history of Rekvina Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Rekvina Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Rekvina Laboratories has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.

Total GSTINs
1
Cancelled / inactive
1

To see the full GST registrations and return filing status of Rekvina Laboratories Limited, buy the company report.

Recent activity

Rekvina Laboratories Limited has 15 board changes on record since 1997: 9 appointments and 6 cessations. The latest: Jay Chintan Patel was appointed as Additional Director on 29 Jan 2026.

Charges
A charge with Bank Of Baroda amounted to Rs. 0.05 Cr with Charge ID 90100140 was registered on 30 Dec 2203.
Filing
Rekvina Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Jay Chintan Patel was appointed as Additional Director.
Ceased
Jitendra Laljibhai Doshi ceased to be Additional Director.
Ceased
Vibha Mukesh Shah ceased to be Director.
Appointed
Prateek Jain was appointed as Additional Director.
AGM
Rekvina Laboratories Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Appointed
Surbhit Mukesh Shah was appointed as Director.
Ceased
Chetanbhai Jayantibhai Patel ceased to be Additional Director.
Ceased
Dhruvalkumar Jayantilal Patel ceased to be Additional Director.
Appointed
Ila Rajendra Pathak was appointed as Director.
Ceased
Mahendra Shantilal Dalal ceased to be Additional Director.

19 earlier events are in the company report.

Frequently asked questions

Rekvina Laboratories is an active public limited company based in Vadodara, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 November 1988 (38+ years old) and is registered under CIN L24231GJ1988PLC011458. Listed on BSE: 526075.

Rekvina Laboratories reported revenue of ₹1.27 Cr for FY 2025-26 based on standalone financials.

Rekvina Laboratories has 5 current directors:

The latest financial statements of Rekvina Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

No. Rekvina Laboratories has 1 GST registration on record and it is cancelled or inactive.

The CIN (Corporate Identification Number) of Rekvina Laboratories is L24231GJ1988PLC011458. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Rekvina Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 526075).

Rekvina Laboratories has 8 court cases on record: 5 filed by the company and 3 filed against it. Most are in the high courts.

Rekvina Laboratories was incorporated on 01 November 1988, making it 38+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Rekvina Laboratories has 81 deals on record (81 market trades); the latest was in June 2018.